New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
05:54 EDTTEVA, AAStocks with implied volatility movement; TEVA AA
Stocks with implied volatility movement; Teva (TEVA) 30, Alcoa (AA) 40 according to iVolatility.
News For TEVA;AA From The Last 14 Days
Check below for free stories on TEVA;AA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
September 17, 2014
08:05 EDTTEVAEagle Pharm says Teva requests motion to dismiss Bendamustine lawsuit
Subscribe for More Information
September 16, 2014
09:36 EDTAAActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL NFLX TSLA YHOO FB PBR MU AA TWTR WMT
September 15, 2014
18:34 EDTAAOn The Fly: After Hours Movers
Subscribe for More Information
16:17 EDTAAAlcoa announces proposed offering of 25M depositary shares
Subscribe for More Information
September 12, 2014
09:01 EDTTEVATeva to present Copaxone gene expression analysis
Subscribe for More Information
08:06 EDTTEVATeva presents new clinical safety data in RRMS patients treated with Laquinimod
Teva (TEVA) and Active Biotech (ACTI) announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis, or RRMS, who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. The pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in the core studies where currently identified risks were observed within the first months of laquinimod treatment. In the pooled safety analysis, rates of adverse events, or AEs, and serious AEs were lower in the open-label extensions than in the core studies and less than three percent of patients discontinued treatment due to AEs during these extensions. Additionally, shifts to potentially significant laboratory values were considerably lower in patients exposed to at least two years of laquinimod.
08:03 EDTTEVATeva, Active Biotech present laquinimod follow-up data
Subscribe for More Information
September 11, 2014
09:31 EDTTEVATeva announces new data from Phase IIIb GLACIER study
Subscribe for More Information
09:01 EDTAAAlcoa signs multiyear supply contract with Boeing valued at over $1B
Alcoa (AA) has signed a long-term contract to supply aluminum sheet and plate products to Boeing (BA). The multiyear contract, valued at more than $1B, is the largest ever between the two companies. Notably, the agreement makes Alcoa sole supplier to Boeing for wing skins on all of its metallic structure airplanes. Alcoa plate products, used in applications such as wing ribs, wing skins or other structural parts of the aircraft, will also be on every Boeing platform, including the 787 Dreamliner. Finally, the agreement establishes a foundation for continued collaboration on new, high-strength and corrosion-resistant alloys, including aluminum-lithium that could be used for complex structural applications.
03:27 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
September 10, 2014
14:25 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
September 9, 2014
10:10 EDTAAOn the Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AMC Entertainment (AMC) initiated with a Hold at Topek... AMRI (AMRI) initiated with an Overweight at JPMorgan... Alcoa (AA) initiated with an Outperform at Bernstein... Alumina (AWC) initiated with a Market Perform at Bernstein... American Airlines (AAL) initiated with an Outperform at Credit Suisse... Catalent (CTLT) initiated with a Buy at BofA/Merrill... Chimerix (CMRX) initiated with a Buy at Cantor... Delta Air Lines (DAL) initiated with an Outperform at Credit Suisse... Enable Midstream (ENBL) initiated with an Outperform at BMO Capital... Enbridge Energy (EEP) initiated with a Market Perform at BMO Capital... Endocyte (ECYT) initiated with a Buy at Cantor... EnerNOC (ENOC) initiated with an Outperform at Pacific Crest... Enterprise Products (EPD) initiated with an Outperform at BMO Capital... Good Times Restaurants (GTIM) initiated with a Buy at Roth Capital... JetBlue (JBLU) initiated with an Underperform at Credit Suisse... Kinder Morgan Energy (KMP) initiated with a Market Perform at BMO Capital... MEI Pharma (MEIP) initiated with a Buy at Cantor... ONEOK Partners (OKS) initiated with a Market Perform at BMO Capital... Southwest (LUV) initiated with a Neutral at Credit Suisse... Spectra Energy Partners (SEP) initiated with an Outperform at BMO Capital... TC PipeLines (TCP) initiated with a Market Perform at BMO Capital... TECO Energy (TE) initiated with a Neutral at Citigroup... Targa Resources Partners (NGLS) initiated with a Market Perform at BMO Capital... United Continental (UAL) initiated with an Outperform at Credit Suisse... Weibo (WB) initiated with a Buy at T.H. Capital... Williams Partners (WPZ) initiated with a Market Perform at BMO Capital.
08:10 EDTAAAlcoainitiated with an Outperform at Bernstein
Subscribe for More Information
September 8, 2014
12:40 EDTTEVAFTC sues AbbVie over blocking of AndroGel generics
The Federal Trade Commission has filed a complaint in federal district court charging several pharmaceutical companies with "illegally blocking American consumers’ access to lower-cost versions of the blockbuster drug AndroGel." The FTC's complaint alleges that AbbVie (ABBV) and its partner Besins Healthcare filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of the testosterone replacement drug AndroGel. While the lawsuits were pending, AbbVie then entered into an anticompetitive pay-for-delay settlement agreement with Teva Pharmaceuticals (TEVA) to further delay generic drug competition, the FTC claims. Reference Link
09:27 EDTTEVALeerink biotech analyst holds a luncheon meeting with a conference call
Biotech Analyst Schwartz provides an update on key trends and controversies for marketed MS therapies and discusses new data presented at ACTRIMS-ECTRIMS at a Luncheon Meeting with an Analyst/Industry conference call to be held in Boston on September 11 at 12:15 pm.
08:02 EDTTEVATeva completes Reslizumab Phase III program
Subscribe for More Information
September 5, 2014
10:05 EDTTEVAOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Actavis (ACT) initiated with a Buy at ISI Group... Akamai (AKAM) initiated with a Buy at UBS... Alexion (ALXN) initiated with a Buy at SunTrust... Allegion (ALLE) initiated with a Buy at Buckingham... Allergan (AGN) initiated with a Buy at ISI Group... Aviat Networks (AVNW) initiated with a Neutral at H.C. Wainwright... Celgene (CELG) initiated with a Buy at SunTrust... EZCORP (EZPW) initiated with a Hold at Jefferies... Eaton (ETN) initiated with a Neutral at Buckingham... Emerson (EMR) initiated with a Neutral at Buckingham... HMS Holdings (HMSY) initiated with an Overweight at Stephens... Incyte (INCY) initiated with a Buy at SunTrust... Ingersoll-Rand (IR) initiated with a Neutral at Buckingham... Insmed (INSM) initiated with an Outperform at Cowen... Intercept (ICPT) initiated with an Outperform at Cowen... Johnson & Johnson (JNJ) initiated with an Outperform at BMO Capital... Lennox (LII) initiated with a Neutral at Buckingham... Mylan (MYL) initiated with a Hold at ISI Group... Orion Engineered Carbons (OEC) initiated with a Buy at Goldman... Parker-Hannifin (PH) initiated with a Buy at Buckingham... Pentair (PNR) initiated with a Neutral at Buckingham... Pharmacyclics (PCYC) initiated with a Neutral at SunTrust... Rockwell Automation (ROK) initiated with a Neutral at Buckingham... Sabre (SABR) initiated with an Outperform at Oppenheimer... Santander Consumer (SC) initiated with a Buy at Jefferies... Springleaf (LEAF) initiated with a Buy at Jefferies... Susser Petroleum (SUSP) initiated with a Neutral at Credit Suisse... Teva (TEVA) initiated with a Buy at ISI Group... Valeant (VRX) initiated with a Buy at ISI Group... WESCO (WCC) initiated with a Neutral at Buckingham... Watsco (WSO) initiated with a Neutral at Buckingham... Weyerhaeuser (WY) initiated with a Neutral at JPMorgan... World Acceptance (WRLD) initiated with a Hold at Jefferies.
September 4, 2014
17:16 EDTTEVATeva initiated with a Buy at ISI Group
Subscribe for More Information
08:02 EDTTEVATeva launches generic Baraclude in U.S.
Teva (TEVA) announces the launch of the generic equivalent to Baraclude tablets in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity. Baraclude is marketed by Bristol-Myers Squibb (BMY).
07:21 EDTTEVAMedidata can obtain major new platform customers, says Stifel
Noting that Medidata (MDSO) partners with Veeva, Stifel believes that a number of Veeva (VEEV) customers could become Medidata platform customers, especially if they already use Medidata for R&D and clinical trial solutions. The firm identifies Merck (MRK), Gilead (GILD), and Teva (TEVA) as companies that may become platform clients for Medidata. Stifel keeps a $55 price target and Buy rating on Medidata.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use